moxonidine has been researched along with Cardiac Hypertrophy in 3 studies
moxonidine: structure given in first source
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxonidine is a second-generation, centrally acting antihypertensive drug with a distinctive mode of action." | 2.39 | Pharmacology of moxonidine, an I1-imidazoline receptor agonist. ( Ernsberger, P; Haxhiu, MA; Kaan, EC; Papp, JG; Ziegler, D, 1996) |
| "Pretreatment with efaroxan (a selective I(1)-imidazoline receptor antagonist) or rauwolscine (a selective alpha(2)-adrenoceptor antagonist) inhibited the moxonidine-induced increases in ANP secretion and interstitial ANP concentration and decrease in pulse pressure." | 1.32 | Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy. ( Cao, C; Kang, CW; Kim, SH; Kim, SZ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, C | 1 |
| Kang, CW | 1 |
| Kim, SZ | 1 |
| Kim, SH | 1 |
| Ziegler, D | 1 |
| Haxhiu, MA | 1 |
| Kaan, EC | 1 |
| Papp, JG | 1 |
| Ernsberger, P | 1 |
| Van Kerckhoven, R | 1 |
| van Veen, TA | 1 |
| Boomsma, F | 1 |
| Saxena, PR | 1 |
| Schoemaker, RG | 1 |
1 review available for moxonidine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cats; Dogs; Heart Rate; Hypertension | 1996 |
2 other studies available for moxonidine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Atrial Fu | 2004 |
Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
Topics: Animals; Blood Pressure; Cardiomegaly; Catecholamines; Collagen; Disease Models, Animal; Dose-Respon | 2000 |